Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | KRAS | P01116 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707225 | 0.86 | CHRM4 (0.47) | QDPRSOS1MEN1KMT2AKRAS | |
| SCHEMBL6712511 | 0.83 | QDPR (0.52) | QDPRSOS1KMT2ASLC9A1TLR7 | |
| SCHEMBL25691218 | 0.82 | ALDH1A1 (0.48) | QDPRMEN1KMT2AALDH1A1 | |
| SCHEMBL27016299 | 0.82 | HDAC4 (0.46) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6712503 | 0.81 | QDPR (0.54) | QDPRSOS1MEN1KMT2APDE4B | |
| SCHEMBL13917718 | 0.78 | MEN1 (0.72) | QDPRMEN1KMT2AKDM4EBRD4 | |
| SCHEMBL3378363 | 0.78 | HTR1A (0.46) | MEN1KMT2APDE4BTLR7ALDH1A1 | |
| SCHEMBL17660573 | 0.77 | LMNA (0.49) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL17660575 | 0.76 | CHRM4 (0.46) | TLR7 | |
| SCHEMBL5670914 | 0.76 | QDPR (0.57) | QDPRSOS1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-6673555-B1 | USE OF SREBP CLEAVAGE-ACTIVATING PROTEIN (SCAP) TO SCREEN FOR AGENTS HAVING SCAP BINDING CHARACTERISTICS; USE IN COMBATING DISEASES ASSOCIATED WITH ELEVATED BLOOD LIPID LEVELS; SREBP: STEROL REGULATORY ELEMENT BINDING PROTEIN | SMITHKLINE BEECHAM CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-20030224347-A1 | Pharmaceutical compositions | GRAND-PERRET THIERRY ANDRE REG (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030224348-A1 | Methods of screening for SCAP antagonists | GRAND-PERRET THIERRY ANDRE REG (FR) | 2003-12-04 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| EP-1196783-A2 | SCREENING FOR THERAPEUTIC AGENTS BEING SCAP ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001006261-A2 | SCREENING FOR THERAPEUTIC AGENTS BEING SCAP ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | QDPR 1864/4885SOS1 3728/4885MEN1 4787/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | QDPR 658/4885SOS1 4458/4885MEN1 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.